An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder - University of Chicago (ClinicalTrials.gov, 2025)
Exported from Psilocybin Research Publication Tracker: https://psilocybin-research.com